Mounjaro vs Wegovy vs Ozempic: an honest 2026 comparison

TL;DR

• Three brand names, two molecules - Ozempic and Wegovy are both semaglutide; Mounjaro is tirzepatide.
• Tirzepatide is the more potent of the two - in the head-to-head SURMOUNT-5 trial it produced −20.2% versus semaglutide's −13.7% at 72 weeks.
• It was also the better tolerated - GI side effects severe enough to stop treatment hit 5.6% on semaglutide versus 2.7% on tirzepatide.
• Semaglutide holds the larger cardiovascular record - SELECT found a 20% reduction in major adverse cardiovascular events across 17,604 adults.
• Mounjaro received NPRA approval in Malaysia on 30 August 2025; Ozempic is registered mainly for type-2 diabetes, so weight-loss use there is off-label.
• A 2025 NPRA safety directive flagged aspiration risk during anaesthesia - tell your surgeon or anaesthetist before any procedure.

MAB-reviewed and cleared for the Malaysian market (Jun 2026). Educational content, not medical advice or a recommendation of any specific product. We have no commercial stake in which molecule a patient ends up on; this is a plain reading of the published evidence. Compound and trial data lead; anecdotal reports are labelled as such. Doses appear only as they were studied - nothing here is a dosing instruction.

---

Three brand names dominate the weight-loss-injection conversation in Malaysia - Ozempic, Wegovy and Mounjaro - but they represent only two drugs. Ozempic and Wegovy are both semaglutide; Mounjaro is tirzepatide. In the only head-to-head trial, tirzepatide produced more weight loss - about 20% versus 14% over 72 weeks - though the two share a side-effect profile and semaglutide carries the larger cardiovascular-outcomes record. The honest bottom line, up front: the better choice is the one matched to the patient, not the one with the highest number.

Here's the detail behind that.

First, untangle the names

Ozempic and Wegovy are the same molecule: semaglutide. The difference is the licence and the dose. Ozempic is the brand licensed for type-2 diabetes; Wegovy is the same semaglutide licensed for weight management, and is titrated to a higher weekly ceiling. Same drug, two packages, two approved jobs - and the strengths themselves are a prescriber's business, not a website's.

Mounjaro is a different molecule: tirzepatide. This is the one genuine difference in the trio - and a real one, because tirzepatide works on two receptors, not one.

So the honest comparison isn't three-way. It's semaglutide vs tirzepatide, with the brand name depending on what it's licensed for and what's in stock.

The comparison at a glance

The mechanism, briefly - because it explains the rest

Semaglutide is a GLP-1 receptor agonist. GLP-1 is a gut hormone that signals fullness, slows stomach emptying and tells the brain you've eaten - so the drug turns down appetite and the background hum of food preoccupation.

Tirzepatide is a dual GIP + GLP-1 receptor agonist. It does everything semaglutide does and adds a second pathway, GIP, which appears to improve insulin sensitivity and may make the appetite effect easier to tolerate at a given level of weight loss. That extra lever is the leading explanation for why, head to head, it tends to do more.

What the trials actually show

Let the numbers speak. In STEP 1, semaglutide at its weight-management strength produced a mean −14.9% body weight at 68 weeks (Wilding et al., NEJM 2021). In SURMOUNT-1, tirzepatide reached 16.0% / 21.4% / 22.5% across its low, middle and top dose arms over 72 weeks (Jastreboff et al., NEJM 2022). And in the first direct comparison, SURMOUNT-5, tirzepatide produced −20.2% versus semaglutide's −13.7% at 72 weeks - about 47% greater relative weight loss (Aronne et al., NEJM 2025).

So on weight loss alone, tirzepatide is the more potent of the two. That's the clear read, and we won't soften it.

But here's the nuance the leaderboard misses: in that same head-to-head trial, gastrointestinal side effects severe enough to stop treatment were more common with semaglutide (5.6%) than tirzepatide (2.7%). "Stronger" did not mean "harder to tolerate." Potency and tolerability are separate axes, and they don't always point the same way.

These aren't only weight-loss drugs

A point that rarely makes the brand comparisons but should: these molecules have cardiovascular and metabolic effects beyond the scale. The SELECT trial (semaglutide at its weight-management strength, 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes) found a 20% reduction in major adverse cardiovascular events - heart attack, stroke, cardiovascular death - over a mean of about 40 months (Lincoff et al., NEJM 2023). The benefit appeared only partly explained by weight loss, pointing to effects on blood pressure, lipids, inflammation and the vessels themselves. A post-hoc analysis of SURMOUNT-5 projected a somewhat larger long-term cardiovascular-risk reduction for tirzepatide, driven by the greater weight change.

Judged only as "which drops the scale most," tirzepatide leads. Judged as cardiometabolic medicine, both do meaningful work, and semaglutide carries the larger dedicated outcomes dataset so far.

The side-effect profile they share

Because they share a mechanism family, they share a side-effect family:

• Gastrointestinal effects (nausea, vomiting, diarrhoea, constipation) are most common, usually mild-to-moderate and concentrated during dose escalation. They're the leading reason people stop.
• Gallbladder issues and, rarely, pancreatitis can occur with significant weight loss.
• Muscle, hair and facial-volume changes are real but are largely consequences of rapid weight loss itself, not unique drug toxicities - covered in their own pieces (muscle loss · "Ozempic face" and hair).
• A 2025 NPRA safety directive flagged that, because these drugs slow stomach emptying, they raise aspiration risk during anaesthesia - so tell your surgeon or anaesthetist before any procedure.

Who should be cautious or avoid them: anyone with a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, or who is pregnant or planning pregnancy. Screening for exactly this is what a prescriber is for.

What patients report that the trials don't measure

Trials measure weight, waist, labs and events. They don't capture one of the most consistently described subjective effects: the quieting of "food noise" - the constant low-level mental chatter about eating. This is patient-reported, not a controlled trial endpoint, so we flag it as anecdotal - but it's described so consistently, across both molecules, that it's worth naming. For many people it's what makes a calorie deficit feel sustainable rather than like deprivation.

What's actually available in Malaysia (2026)

Mounjaro (tirzepatide) received NPRA approval on 30 August 2025 (registration MAL24026013AZ) for obesity (BMI ≥30, or ≥27 with a weight-related condition) and type-2 diabetes - prescription-only. Ozempic (semaglutide) is NPRA-registered primarily for type-2 diabetes; weight-loss use is off-label and physician-directed. Wegovy (semaglutide, weight-management licence) has launched for weight management. None sit on open pharmacy shelves - they're prescription medicines obtained through licensed clinics, and supply has fluctuated, broadening through 2026 as tirzepatide entered the market. (A newer oral semaglutide pill for weight loss was approved in the US in late 2025; its availability in Malaysia will follow local NPRA registration.)

The bottom line - and where to start

Stay agnostic, because the data support it: if maximum weight loss is the priority and the patient tolerates titration, tirzepatide has the stronger efficacy evidence. If a dedicated cardiovascular-outcomes record matters most, semaglutide currently has the larger one. Tolerability is individual - the only reliable way to know how someone responds is supervised titration with the option to switch. This is a matching problem, not a ranking problem, and answering it is the entire point of having a physician screen, titrate, monitor and adjust rather than picking a brand off a list. The drug is the easy part; the supervision is where the outcome is decided.

Explore it with verified supply. Every Vivre Labs lot is independently tested and the certificate of analysis is published, so you know exactly what is in the vial. Explore semaglutide.

Related reading

• Keeping the weight off after you stop - what happens when you stop - and how to keep it off
• Losing fat, not muscle, on a GLP-1 - keeping muscle while you lose fat
• "Ozempic face" and hair loss, explained - "Ozempic face" and hair loss, explained
• What weight-loss injections cost in KL - what it actually costs in KL
• Tirzepatide vs retatrutide - what's coming after Mounjaro
• Do you need a doctor for this? - what supervision actually protects you from
• The four compounds, side by side - semaglutide vs tirzepatide vs retatrutide vs CagriSema
• How GLP-1 agonists actually work - the mechanism in plain terms
• The semaglutide patent cliff - where semaglutide's patents have expired, and why that hasn't reached this region
• GLP-1 beginner's guide: what to expect - your first months, start to finish

---

Educational content, not medical advice and not an endorsement of any product. Ozempic, Wegovy and Mounjaro are prescription medicines that require screening, prescription and monitoring by a licensed physician. Trial figures describe study populations; individual results vary. Health and treatment claims for the Malaysian market were reviewed and cleared by MAB (Jun 2026).

Primary references

• Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989–1002.
• Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205–216.
• Aronne LJ, et al. Tirzepatide versus semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025. (head-to-head: −20.2% vs −13.7% at 72 weeks)
• Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med. 2023;389:2221–2232. (20% MACE reduction)
• Mamas MA, et al. Tirzepatide compared with semaglutide and 10-year cardiovascular disease risk reduction: post-hoc analysis of SURMOUNT-5. Eur Heart J Open. 2025;5(5):oeaf117.
• Malaysia NPRA registration: Mounjaro (tirzepatide) MAL24026013AZ, approved 30 Aug 2025.